Deepak K Gupta1, Robert P Giugliano2, Christian T Ruff2, Brian Claggett3, Sabina Murphy2, Elliott Antman2, Michele F Mercuri4, Eugene Braunwald2, Scott D Solomon3. 1. Vanderbilt Heart and Vascular Institute, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee; Vanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address: d.gupta@vanderbilt.edu. 2. TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States. 3. Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States. 4. Daiichi Sankyo Pharma Development, Edison, New Jersey.
Abstract
BACKGROUND:Atrial fibrillation (AF) is associated with increased risk for thromboembolism and death; however, the relationships between cardiac structure and function and adverse outcomes among individuals with AF are incompletely understood. METHODS: The Effective Anticoagulation with Factor Xa Next Generation in AF-Thrombolysis in Myocardial Infarction 48 study tested the once-daily oral factor Xa inhibitor edoxaban in comparison with warfarin for the prevention of stroke (ischemic or hemorrhagic) or systemic embolism in 21,105 subjects with nonvalvular AF and increased risk for thromboembolic events (CHADS2 score ≥ 2). In a prospective substudy of 971 subjects who underwenttransthoracic echocardiography at baseline, Cox proportional hazards models were used to evaluate associations between cardiac structure and function and the risks for death and thromboembolism (ischemic stroke, transient ischemic attack, or systemic embolism). RESULTS: Over a median follow-up period of 2.5 years, 89 deaths (9.2%) and 48 incident thromboembolic events (4.9%) occurred in 971 subjects. In models adjusted for CHADS2 score, aspirin use, and randomized treatment, larger left ventricular (LV) end-diastolic volume index (hazard ratio per 1 SD [12.9 mL/m(2)], 1.49; 95% CI, 1.16-1.91) and higher LV filling pressures measured by E/e' ratio (hazard ratio per 1 SD [4.6], 1.32; 95% CI, 1.08-1.61) were independently associated with increased risks for death. E/e' ratio > 13 significantly improved the prediction of death beyond clinical factors alone. No features of cardiac structure and function were independently associated with thromboembolism in this population. Findings were similar when adjusted for CHA2DS2-VASc score in place of CHADS2 score. CONCLUSIONS: In a contemporary population of patients with AF at increased risk for thromboembolic events, larger LV size and higher filling pressures were significantly associated with increased risk for death, but neither left atrial nor LV measures were associated with thromboembolic risk. LV size and filling pressures may help identify patients with AF at increased risk for death.
RCT Entities:
BACKGROUND:Atrial fibrillation (AF) is associated with increased risk for thromboembolism and death; however, the relationships between cardiac structure and function and adverse outcomes among individuals with AF are incompletely understood. METHODS: The Effective Anticoagulation with Factor Xa Next Generation in AF-Thrombolysis in Myocardial Infarction 48 study tested the once-daily oral factor Xa inhibitor edoxaban in comparison with warfarin for the prevention of stroke (ischemic or hemorrhagic) or systemic embolism in 21,105 subjects with nonvalvular AF and increased risk for thromboembolic events (CHADS2 score ≥ 2). In a prospective substudy of 971 subjects who underwent transthoracic echocardiography at baseline, Cox proportional hazards models were used to evaluate associations between cardiac structure and function and the risks for death and thromboembolism (ischemic stroke, transient ischemic attack, or systemic embolism). RESULTS: Over a median follow-up period of 2.5 years, 89 deaths (9.2%) and 48 incident thromboembolic events (4.9%) occurred in 971 subjects. In models adjusted for CHADS2 score, aspirin use, and randomized treatment, larger left ventricular (LV) end-diastolic volume index (hazard ratio per 1 SD [12.9 mL/m(2)], 1.49; 95% CI, 1.16-1.91) and higher LV filling pressures measured by E/e' ratio (hazard ratio per 1 SD [4.6], 1.32; 95% CI, 1.08-1.61) were independently associated with increased risks for death. E/e' ratio > 13 significantly improved the prediction of death beyond clinical factors alone. No features of cardiac structure and function were independently associated with thromboembolism in this population. Findings were similar when adjusted for CHA2DS2-VASc score in place of CHADS2 score. CONCLUSIONS: In a contemporary population of patients with AF at increased risk for thromboembolic events, larger LV size and higher filling pressures were significantly associated with increased risk for death, but neither left atrial nor LV measures were associated with thromboembolic risk. LV size and filling pressures may help identify patients with AF at increased risk for death.
Authors: Line Melgaard; Anders Gorst-Rasmussen; Deidre A Lane; Lars Hvilsted Rasmussen; Torben Bjerregaard Larsen; Gregory Y H Lip Journal: JAMA Date: 2015-09-08 Impact factor: 56.272
Authors: Sherif F Nagueh; Christopher P Appleton; Thierry C Gillebert; Paolo N Marino; Jae K Oh; Otto A Smiseth; Alan D Waggoner; Frank A Flachskampf; Patricia A Pellikka; Arturo Evangelista Journal: J Am Soc Echocardiogr Date: 2009-02 Impact factor: 5.251
Authors: Christian T Ruff; Robert P Giugliano; Elliott M Antman; Sharon E Crugnale; Tomas Bocanegra; Michele Mercuri; James Hanyok; Indravadan Patel; Minggao Shi; Dan Salazar; Carolyn H McCabe; Eugene Braunwald Journal: Am Heart J Date: 2010-10 Impact factor: 4.749
Authors: H Okura; Y Takada; T Kubo; K Iwata; S Mizoguchi; H Taguchi; I Toda; J Yoshikawa; K Yoshida Journal: Heart Date: 2006-01-31 Impact factor: 5.994
Authors: H C Dittrich; L A Pearce; R W Asinger; R McBride; R Webel; M Zabalgoitia; G D Pennock; R E Safford; R M Rothbart; J L Halperin; R G Hart Journal: Am Heart J Date: 1999-03 Impact factor: 4.749
Authors: Navkaranbir S Bajaj; Vikas Bhatia; Kumar Sanam; Sameer Ather; Taimoor Hashim; Charity Morgan; Gregg C Fonarow; Navin C Nanda; Sumanth D Prabhu; Chris Adamopoulos; Raya Kheirbek; Wilbert S Aronow; Ross D Fletcher; Stefan D Anker; Ali Ahmed; Prakash Deedwania Journal: Am J Cardiol Date: 2014-09-15 Impact factor: 2.778
Authors: Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman Journal: N Engl J Med Date: 2013-11-19 Impact factor: 91.245
Authors: Riccardo M Inciardi; Robert P Giugliano; Brian Claggett; Deepak K Gupta; Alvin Chandra; Christian T Ruff; Elliott M Antman; Michele F Mercuri; Michael A Grosso; Eugene Braunwald; Scott D Solomon Journal: Eur J Heart Fail Date: 2019-11-27 Impact factor: 15.534
Authors: Ethan D Borre; Adam Goode; Giselle Raitz; Bimal Shah; Angela Lowenstern; Ranee Chatterjee; Lauren Sharan; Nancy M Allen LaPointe; Roshini Yapa; J Kelly Davis; Kathryn Lallinger; Robyn Schmidt; Andrzej Kosinski; Sana M Al-Khatib; Gillian D Sanders Journal: Thromb Haemost Date: 2018-10-30 Impact factor: 6.681
Authors: Jin Man Jung; Yong Hyun Kim; Sungwook Yu; Kyungmi O; Chi Kyung Kim; Tae Jin Song; Yong Jae Kim; Bum Joon Kim; Sung Hyuk Heo; Kwang Yeol Park; Jeong Min Kim; Jong Ho Park; Jay Chol Choi; Man Seok Park; Joon Tae Kim; Kang Ho Choi; Yang Ha Hwang; Jong Won Chung; Oh Young Bang; Gyeong Moon Kim; Woo Keun Seo Journal: J Clin Neurol Date: 2019-10 Impact factor: 3.077